Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Disposition of [14C]-LY3214996 in Healthy Male Subjects
NCT04033341Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Aug 2019
- Primary completion
- Sep 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of temuterkib in solid tumor, sponsored by Eli Lilly and Company. Primary endpoints: Urinary Excretion of LY3214996 Radioactivity Over Time Expressed As A Percentage of the Total Radioactive Dose Administered at Day 8 and Fecal Excretion of LY3214996 Radioactivity Over Time Expressed As A Percentage of the Total Radioactive Dose Administered at Day 8. Started Aug 2019; status: completed.
02
Drugs
temuterkib
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT04033341.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04033341.